EUCTR2011-004826-87-ESActive, not recruitingPhase 1
Randomized multicentric open-label phase III clinical trial to evaluate the efficacy of continual treatment versus discontinuation based in the presence of prodromes in a first episode of non-affective psychosis. - Discontinuation clinical trial in first episode of non-affective psychosis
Fundacion Progreso y Salud0 sites0 target enrollmentStarted: February 28, 2012Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •- Adult age 18 to 55 years old
- •- Non-affective psychosis diagnosis (schizophrenia, schizoaffective, schizophreniform disorders, acute psychosis, other psychosis DSM-IV)
- •- Antipsychotic treatment for 12 months since clinical stabilization. Clinical stabilization is defined in case of admission by medical discharge (not including voluntary discharge). In case of voluntary discharge or no admission to hospital, clinical stabilization can be defined by the psychiatrist according to medical history and the information provided by the family.
- •- No changes in the antipsychotic doses in the last 4 months
- •- No suicide attempts in the last 12 months
- •- Shows remission criteria (Van Os y cols., 2006)
- •- Signed informed consent form
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 104
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •- Not fluent in Spanish
- •- Takes mood stabilizers (Lithium, antiepileptic drugs...)
- •- Dependency on alcohol or other substances of abuse (cannabis, cocaíne...)
- •- History of Craneo-encephalic Trauma with loss of consciousness for more than 1 hour, stroke or other CNS disorders
- •- IQ less than 70
- •- Suicide attempt from stabilization
- •- Pregnancy or planning to become pregnant during the study
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Strong Treat 1 to 4StrongyloidiasisEUCTR2011-002784-24-GBSacro Cuore - Don Calabria Hospital400
Active, not recruiting
Phase 1
Clinical trial comparing azacitidine plus pevonedistat versus azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for standard induction chemotherapyMedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864Acute Myeloid LeukemiaEUCTR2019-001323-12-PTFundación PETHEMA466
Completed
Phase 3
Phase III clinical study to evaluate the effectivity of Comvac4 vaccine in 6 to 7weeks infantsCTRI/2017/01/007706Bharat Biotech International Limited240
Active, not recruiting
Phase 1
A randomized open-label multicenter phase III trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for untreated patients with systemic light-chain (AL) amyloidosisAL AmyloidosisMedDRA version: 14.1Level: HLGTClassification code 10035227Term: Plasma cell neoplasmsSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2010-022395-31-DKE.M.N. - EUROPEAN MYELOMA NETWORK110
Completed
Phase 3
An international trial with a new standard of care for patients with AL amyloidosis.ntreated systemic light chain amyloidosisAmyloidUntreated systemic light chain amyloidosisCancer - MyelomaACTRN12611000561987Australasian Leukaemia and Lymphoma Group (ALLG)110